Global Animal Parasiticides Market to grow at a CAGR of 5.87% during the period 2017-2021


Orbis Research Present’s Global Animal Parasiticides Market 2017-2021 has been prepared based on an in-depth market analysis with inputs from industry experts.


About Animal Parasiticides

The Global Animal Parasiticides Market to grow at a CAGR of 5.87% during the period 2017-2021.

Veterinary parasiticides or antiparasitics are products that kill parasites that infest livestock, pets, and other animals. The global animal parasiticides market is expected to grow at a moderate pace driven by the rise in demand for animal proteins and the increased focus on food safety. The increase in animal population will also help boost market growth. Bayer HealthCare, Elanco, Merial, Merck Animal Health, and Zoetis are the major vendors in the market. These vendors offer a wide portfolio of products in various segments such as animal diagnostics, animal vaccines, animal pharmaceuticals, and animal feed additives. These products are intended for use in companion animals and livestock. These products have active ingredients that kill or inhibit growth and a series of non-active ingredients such as stabilizers and solvents.

Get a PDF Sample of Global Animal Parasiticides Market Report at:

Covered in this report

The report covers the present scenario and the growth prospects of the global animal parasiticides market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:




Global Animal Parasiticides Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Place a Purchase Order Global Animal Parasiticides Market Report at:

Key vendors

Bayer HealthCare


Merck Animal Health



Other prominent vendors

Animal Medics

Biogénesis Bagó


Boehringer Ingelheim

Ceva Santé Animale

Dechra Pharmaceuticals

ECO Animal Health


Indian Immunologicals

Lillidale Animal Health

Mobedco-Vet (The Arab Pesticides & Veterinary Drugs)




Phibro Animal Health




Market driver

Rise in incidences of zoonotic diseases.

For a full, detailed list, view our report

Market challenge

Lengthy regulatory approval process.

For a full, detailed list, view our report

Market trend

Vertical integration in livestock industry.

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2021 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Companies Mentioned:

Bayer HealthCare, Elanco, Merck Animal Health, Merial, Zoetis, Animal Medics, Biogénesis Bagó, Bio-Vet, Boehringer Ingelheim, Ceva Santé Animale, Dechra Pharmaceuticals, ECO Animal Health, Huvepharma, Indian Immunologicals, Lillidale Animal Health, Mobedco-Vet (The Arab Pesticides & Veterinary Drugs), Neogen, Norbrook, Orion, Phibro Animal Health, Vétoquinol, Virbac, and Vitafor.

Dr. Kambiz Silani Hosting ZOCULAR „Dry Eye Spa” Events at Warner Music Group and SAG With the „Dry Eye Guys”

    LOS ANGELES, CA, March 30, 2017 /24-7PressRelease/ — This spring Local Eye Doctor to the stars, Dr. Silani (Beverly Hills Optometry), along with The Dry Eye Guys ( Arnold Flores & Arthur Cervantes) will host several „Dry Eye Spa” events with ZOCULAR . Some of their upcoming appearances and media friendly gifting events include: Warner Music Group (Los Angeles) on April 3rd and April 28th, May 3rd at SAG (Screen Actors Guild) followed by a wide variety of events and expos throughout the year. Please visit for a complete schedule of appearances/events/expos featuring ZOCULAR, Dr. Peter Pham (creator of ZOCULAR), Dr. Silani and The Dry Eye Guys. ZOCULAR is the preferred brand that is being used by the „Dry Eye” teams (Dr. Silani and The Dry Eye Guys).

More about „Dry Eye” Teams:
Dry Eye Guys (Arnold Flores and Arthur Cervantes) are focused on offering the best solutions to treat Chronic Dry Eye, eye fatigue, Blepharitis, Demodex and all symptoms related to dry eye related diseases. They travel the world in search of economical and long lasting solutions, teach classes about solutions for Dry Eye Disease (DED) , and host events and benefits nationwide to provide awareness and a solution. Dry Eye Guys have developed the concept of a Dry Eye Spa inside eye care doctors offices. Dry Eye Spas are in high demand and offer the patients a relaxing spa-like environment while providing the medical benefit and treatment for Dry Eye Disease.

The 5-star team at Beverly Hills Optometry and Dr. Kambiz Silani ( offer the latest and most innovative dry eye therapies in a concierge health care setting. Their practice features The Eye Massage by Beverly Hills Optometry and holds the honor of being the 1st site in Beverly Hills to offer this technology, they have developed. Beverly Hills Optometry practice has treated a number of A-list celebrities (Oscar winners, The Royal Family, TV personalities, Grammy winners, and professional athletes) in-office and now partners with entertainment companies and tech companies to address issues with dry eye as well as digital eye strain related to or caused by computer, laptop and cell phone use. Dr. Silani is certified by the National Board of Examiners in Optometry.

Beverly Hills Optometry:
The Eye Massage by Beverly Hills Optometry protocol:
„The Eye Massage by Beverly Hills Optometry” video:

ZOCULAR advances the science of dry eyes with its patent-pending platform of activated natural botanicals. The Zocular platform is a proprietary okra-based formulation with both anti-inflammatory and anti-Demodex properties that targets the source of dry eyes on the eyelid margin. Dry eye is a chronic condition that affects millions of American on a daily basis. The most commonly prescribed treatment for dry eyes is artificial tears. Though this may be intuitively obvious, it is seldom effective for more than a few minutes. This is because over 85% of dry eyes is actually not due to tear deficiency but to inflammation on the eyelid margins. It’s the dirt, bacteria, oil, debris, and mites along the eyelid margin that trigger and perpetuate the cascade of inflammation that leads to dry eyes. Zocular has introduced two new products, ZocuWipeTM and ZocuFoamTM, for the dry eye market. Zocular products requires just one application per day to provide immediate and lasting relief. It’s pH balanced to tears and contains no tea tree oil or other harsh chemicals that can irritate the eye or the skin. Zocular has been clinically demonstrated to kill Ocular Demodex, a leading cause of dry eyes.

The Zocular platform was developed by Dr. Peter Pham, an ophthalmologist with a degree in chemistry who once suffered from dry eyes and became frustrated with the lack of effective treatments for himself and his patients. After 2 years of research and development, the Zocular platform was introduced as the most innovative and proven natural option for the dry eye market.

Non-Lethal Weapon Market Research Forecast, Analysis and Supply Demand Report 2021

Non-Lethal Weapon Market research report provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. Non-Lethal Weapon Market report 2017-2021 focuses on the major drivers and restraints for the key players. The Non-Lethal Weapon Market research report is a professional and in-depth study on the current state of Non-Lethal Weapon Warming Devices Industry.

Analysts forecast the global Non-Lethal Weapon Warming Devices market to grow at a CAGR of 5.88% during the period 2017-2021.

Browse more detail information about Non-Lethal Weapon Market Report at:

The research report covers the present scenario and the growth prospects of the global Non-Lethal Weapon industry for 2017-2021.

Non-lethal weapons, also known as less-lethal weapons, feature less intensity so that these do not kill a living target. These weapons are used in situations to limit the escalation of violence, as well as in scenarios where the use of lethal force is undesirable, or where policy restricts the employment of conventional force.

Key Vendors of Non-Lethal Weapon Market:

  • BAE Systems
  • General Dynamics
  • Kratos Defense & Security Solutions
  • Lamperd Less Lethal
  • Others

Get a PDF Sample of Non-Lethal Weapon Market Research Report at:

The Non-Lethal Weapon Market report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market. Non-Lethal Weapon Market report analyses the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios.

Non-Lethal Weapon Market driver

  • Emphasis on adoption of non-lethal weapons
  • For a full, detailed list, view our report

Non-Lethal Weapon Market challenge

  • Challenges in usage of non-lethal weapons
  • For a full, detailed list, view our report

Non-Lethal Weapon Market trend

  • Emergence of advanced non-lethal laser weapons
  • For a full, detailed list, view our report

Purchase report @

Geographical Segmentation Of Non-Lethal Weapon Market:

  • Non-Lethal Weapon Market in Americas
  • Non-Lethal Weapon Market in APAC
  • Non-Lethal Weapon Market in EMEA

The report provides a basic overview of the Non-Lethal Weapon industry including definitions, segmentation, applications, key vendors, market drivers and market challenges. The Non-Lethal Weapon Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status

Through the statistical analysis, the report depicts the global Non-Lethal Weapon Market including capacity, production, production value, cost/profit, supply/demand and import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

Have any query? ask our expert @

Key questions answered in Non-Lethal Weapon Market report:

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Get Discount on Non-Lethal Weapon Market Research Report at:

List of Exhibits in Non-Lethal Weapon Market report:

  • Exhibit 01: Product offerings
  • Exhibit 02: Impact of drivers
  • Exhibit 03: Impact of drivers and challenges
  • Exhibit 04: Key countries in each region
  • Exhibit 05: Global Non-Lethal Weapon Market shares by geographies 2017
  • Exhibit 06: Global Non-Lethal Weapon Market shares by geographies 2022
  • Exhibit 07: Geographical segmentation by revenue 2017

And continued….


Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750


Cold Plasma Market Research Report by Application, Types, End-User, Regional Analysis and Forecast upto 2026

Cold Plasma Market: Regional Outlook

Europe and North America are prominent markets for cold plasma technology. The impressive growth is driven by the wide presence of global cold plasma companies that have facilitated the accessibility of the technologies. However, Latin America and Asia-Pacific are expected to showcase promising opportunities for companies in the cold plasma market. The regional growth is driven by rising economical and infrastructural activities across various emerging countries, such as China, Thailand, India, and Indonesia. Furthermore, significant technological developments in the electronics and semiconductor industry are expected to fuel the growth of the regional market.

Cold Plasma Market: Overview

Cold plasma, popularly known as non-thermal plasma, is the new cutting edge concept that has wide applications in medical devices. The technology has transformed various medical specialties such as cardiology, dermatology, gastroenterology, and oncology and has been extensively used to assist surgeries related to these areas. Cold plasma has wide ranging applications in bioengineering and to provide antimicrobial treatment food processing propelling the growth of cold plasma market. Recently, the emerging application of cold plasma in cancer therapies is an exciting field and is expected to significantly affect the current researches in cancer therapeutics, driving the evolution of the cold plasma market.

The report offers in-depth insights into key market drivers and restraints, current trends, recent developments, regulatory framework, and emerging opportunities that can be capitalized by the market players. The study is prepared with the help of extensive secondary and primary researches and provides analysis of the market share and size of key applications segments.
Recent technological advances and disruptive technologies expected to alter the competitive dynamics are analyzed in the report. The strategically motivated insights included in the report are intended to help the key market players in identifying lucrative avenues and evidence-based decision making.

Browse full report on Cold Plasma Market –

Cold Plasma Market: Trends and Opportunities

The cold plasma market is primarily driven by unique benefits of cold plasma techniques, demand for innovative production techniques in textile industry and other end-use industries, and soaring concerns of safety and decontamination for processed foods. Cold plasma has been increasingly used to make self-decontaminating filters and in decontamination of various food, particularly meat and poultry packaging. This has propelled the growth of the market.

Considerable capital investment involved in developing cost plasma technologies and their limited commercialization are likely to impede the growth of the market to some extent. However, the expanding applications of cold plasma in various end-use industries such as such as food, agriculture, and polymers and plastics segments across developing nations are the factors boosting the market.

The enhanced efficacy of cold plasma in devising therapies for various types of cancer, such as lung, breast, bladder, and skin is expected to create vast opportunities for the market players along the forecast period. A large number of in-vitro and in-vivo studies have confirmed that cold plasma technology can be used to selectively kill cancer cells. Key characteristics that have boosted the use of cold plasma in cancer therapies are plasma-induced apoptosis and in decreasing the cell migration velocity. This helps in localizing the affected tissue area and by reducing the risk of cancer metastasis.

Cold Plasma Market: Competitive Landscape

Leading players are adopting mergers and acquisitions as the key strategy to consolidate their presence in different emerging markets. Prominent companies operating in this market include Nordson Corporation, Bovie Medical Corporation, Plasmatreat GmbH, Adtec Plasma Technology Co., Ltd., Enercon Industries Corporation, Neoplas Tools GmbH, Europlasma NV, and Tantec A/S Henniker Plasma.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis

The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)

Request for brochure of this report –…

About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453

This release was published on openPR.

GHIT Fund Invests in Late-stage Trial for Child-friendly „Snail Fever” Medicines–One of the Most Debilitating and Widespread Parasitic Diseases in Africa

TOKYO, March 29, 2017 /PRNewswire-USNewswire/ — The Global Health Innovative Technology Fund (GHIT Fund), a unique Japanese public-private partnership formed to battle infectious diseases around the globe, today announced 11 new investments totaling US$23 million* that could help deliver a range of new innovative therapies for a host of debilitating conditions.

This latest round of targeted support includes funding for a Phase 3 clinical trial testing a pediatric formulation of a drug considered the gold standard for treating schistosomiasis, a water-borne parasitic disease linked to an assortment of acute and chronic health problems. Young children are most at risk, but the existing drug is so bitter and hard to swallow that kids often go untreated, leading to serious lifelong health and learning problems.

This clinical trial is one of the most advanced partnerships invested by the GHIT Fund, an organization that combines Japan’s historic leadership in global health and innovation with groundbreaking research from across the globe. The GHIT Fund also is making new investments in two malaria vaccine candidates, while accelerating work to find new drug treatments for malaria, dengue, Chagas disease, cryptosporidiosis and leishmaniasis.

„We’re reaching an exciting phase where GHIT’s approach to partnerships and drug and vaccine development is starting to produce tangible progress towards product deployment that could eventually lead to revolutionary breakthroughs,” said BT Slingsby, MD, PhD, MPH, who is CEO of the GHIT Fund. „We knew that combining Japan’s wealth of biomedical research talent and pharmaceutical capabilities with leading infectious disease experts near and far was likely to be a winning combination, and that’s been validated by the progress we are seeing across a rich diversity of projects.”

A Snail Fever Drug That’s Easy to Swallow

Schistosomiasis, sometimes called „snail fever” because it’s found in freshwater snails, leads to both acute and chronic disease. It’s caused by parasitic worms known as blood flukes and is usually transmitted through contact with infested water. The disease is endemic in 78 developing countries and, according to the World Health Organization, more than 261 million people, including 100 million children, were infected with schistosomiasis in 2015. Some 90 percent of infections occur in Africa, where safe water is often scarce. While rarely fatal, left untreated, the disease can cause anemia, stunted growth, impaired learning ability and chronic inflammation of vital organs.

GHIT Fund’s investment of US$4.7 million, with co-funding from its partners, will support a Phase 3 clinical trial in Africa to evaluate a pediatric formulation of praziquantel (PZQ) in children aged three months to six years. Since the 1970s, the gold-standard of treatment for the disease has been a single oral dose of PZQ used to treat adults and school-aged children. But children under age five who are infected with schistosomiasis are not treated with PZQ under the current policy. And data on the treatment of these children has been sparse and insufficient to define and confirm the best dosing. In addition, the current tablets have a severe bitter taste and the large size of the existing pill makes it difficult or just impossible for small children to swallow. A smaller, more palatable pill that could be administered to children as young as three months old is being developed by the Pediatric Praziquantel Consortium, a nonprofit international public-private partnership involving Astellas Pharma Inc. (Japan), Lygature (The Netherlands), Merck KGaA (Germany), the Swiss Tropical and Public Health Institute, Simcyp Limited (UK), Farmanguinhos (Brazil) and the Schistosomiasis Control Initiative (SCI, UK).

Previous GHIT Fund investments for this project took the formulation through a Phase 2 clinical trial in 2015 and 2016. If successful, the Phase 3 trial will pave the way for regulatory review and prequalification by the World Health Organization (WHO) that would deliver an affordable, effective, child-friendly formulation of PZQ to young victims around the globe.

Biting Back at Malaria

GHIT also announced today a new investment of US$600,000 to develop a unique vaccine for malaria that prevents the malaria parasite from being transmitted from an infected person to a mosquito. Although it won’t protect individuals from malaria, the formulation enables the vaccinated person to become a sort of „human shield” that breaks the vicious cycle of disease, which depends on the malaria parasite being able to move from mosquito to human and then back to mosquito. Known as a „transmission-blocking vaccine,” a successful formulation would be a significant weapon in the global push to eliminate malaria, which killed 438,000 people in 2015, most of them young children in sub-Saharan Africa.

Researchers from the PATH Malaria Vaccine Initiative (US) and Ehime University (Japan) will evaluate a protein (called Pfs230) found in the deadly P. falciparum malaria parasite that appears to produce antibodies that can block disease transmission from humans to mosquitos. The investment from GHIT allows the team to examine small regions of the extremely complex protein via an innovative research tool known as wheat germ cell-free protein synthesis technology. The goal is to harness the transmission-blocking features of the protein to drive development of new vaccine candidates. 

GHIT Fund also is investing US$2.8 million to continue work on a promising malaria vaccine candidate being developed by researchers from Japan’s Research Institute for Microbial Diseases and the Medical Center for Translational and Clinical Research at Osaka University, the Germany-based European Vaccine Initiative (EVI), the Centre National de Recherche et de Formation sur le Paludisme (CNRFP, Burkina Faso), and Nobelpharma Co., Ltd. (Japan). Their formulation, called BK-SE36, has produced encouraging results in early testing, generating an immune response in Japanese adults and in Ugandan volunteers aged 6-32 years. Currently, it is being tested in a Phase 1b clinical trial with young children aged 1-5 years in Burkina Faso, where malaria is rampant. This new investment from the GHIT Fund will enable researchers to evaluate a different formulation of the vaccine in healthy African adults and children, one that contains an additional substance known as an adjuvant that has shown promise in boosting the immune response to the vaccine.  

GHIT will also continue to support four projects that are pursuing new malaria drugs, which are urgently needed to fight the spread of parasites that have become resistant to existing therapies. Over the last few years there has been an emergence of P. falciparum malaria parasites—first in Southeast Asia and just recently in Africa—that can survive an assault from previously powerful antimalarial drugs. Researchers are now racing to develop new treatments that can kill the parasite in a single dose. GHIT’s investments in this work include:

Going After the World’s Most Overlooked Diseases

In its latest round of investments, GHIT is continuing to confront some of the most neglected diseases in the world—diseases that burden more than 1 billion of the world’s poorest people and keep them impoverished by causing a range of chronic mental and physical problems. Fighting these overlooked diseases has been a long-time priority for Japan, and for GHIT, which officially endorsed the London Declaration on Neglected Tropical Diseases in 2014, pledging ongoing funding to defeat them once and for all.

GHIT announced today the following investments in neglected diseases:

The first of its kind in Japan, the GHIT Fund is a public-private partnership between the Japanese government, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, the Wellcome Trust, and UNDP. Launched in April 2013 with an initial commitment of more than US$100 million and now with capital of over US$140 million, the organization taps Japanese research and development (R&D) to fight neglected diseases. GHIT Fund invests and manages a portfolio of development partnerships aimed at neglected diseases that afflict the world’s poorest people. GHIT Fund mobilizes Japanese pharmaceutical companies and academic and research organizations to engage in the effort to get new medicines, vaccines, and diagnostic tools to people who need them most, with Japan quickly becoming a game-changer in global health. For more information, please visit

*All amounts listed at the exchange rate of USD1 = JPY100

For more information, contact:
Katy Lenard at +1-301-280-5719 or

SOURCE Global Health Innovative Technology Fund (GHIT Fund)

The Stone Collector by Eitan Olevsky – 7 stones grant seven extraordinary powers, but these powers are as much curses as blessings, and all come with a cost.

“The Stone Collector by Eitan Olevsky”

Eitan Olevsky’s The Stone Collector is like a cross between Neil Gaiman, Umberto Eco, Jorge Luis Borges, and Paul Coelho. Part murder mystery, part mythic fantasy, part conspiracy theory, part social satire, this truly eccentric novel is built around the notion of seven stones that are as much curses as blessings.

“And as man is composed of the four
elements, so also is the stone,
and so it is [dug] out of man, and you
are its ore, namely by working;
and from you it is extracted, namely by division –
and in you it remains inseparably, namely through science.”
– Rosinus

Eitan Olevsky’s The Stone Collector is like a cross between Neil Gaiman, Umberto Eco, Jorge Luis Borges, and Paul Coelho. Part murder mystery, part mythic fantasy, part conspiracy theory, part social satire, this truly eccentric novel is built around the notion of seven stones that are as much curses as blessings, with a cast of characters that include a devout rabbi, a sexy newscaster, a socially awkward college student, a professional hit man, a drug lord, and an archaeological assistant.  The powers they gain (to kill, to heal, to travel through mirrors, to transmute matter, to speak to spirits, and to make things grow) all come with a cost, as if the stones themselves were linked to the aspect of the psyche that each of the dramatis personae most need to confront and transform.

Indeed, that’s the charm of this perceptive little book.  In telling an apparently fantastical tale about eastern and western alchemy, Atlantis, and the Mythraic Mysteries, it probes relentlessly at our human foibles – our insecurities, our vanities, our regrets, our desires.  The text, riddled with esoteric clues in the form of names, folk legends and mythological references, and of symbols drawn from the animal world and the elements, brings together the eschatological and psychological archetypes of world culture.  The intricately planned chapters can be read, and reread, at many levels, as the plot thickens, the pace quickens, and the interwoven strands begin to feel like double helices.  

For this reader, the stones themselves were mesmerizing, ushering the imagination through a process of inner alchemy, as the groups of chapters activated issues in ways that superimposed the seven chakra wheels of the tantric/yogic system on the Vitruvian Man of the Renaissance… all this, yet always with a wink at the familiar ego formations that make life such an absurd mess, proving that if there’s a young master in this story, it just might be Olevsky himself. 

Eitan Olevsky was born in 1981 in Lima, Peru. His knack for story-telling began at the early age of four, pestering his parents with sleepless nights of fairy tale readings. At five, he was reading Brothers Grimm and La Fontaine, fables imbued in wisdom and magic that would come to show his early fascination for the fantasy genre.

His first attempt at writing a novel was at the age of eight with The Legend of the Magic Wand, which he managed to finish three years later. In 2002, Eitan won first prize at UPC’s “Juegos Florales”, a literary contest from the university where he was studying, with a satire that mocked university life itself. Later, in 2005, he published the satirical novel, El Gran Maestro. Olevsky’s Gran Maestro shows a crazy collection of individuals, portraying with dark humor galore, their lifestyles in Peru during the estranged decade of the 80s and 90s.

You can read the book here: The Stone Collector

Media Contact
Company Name: ContentoNow
Contact Person: Netanel Semrik
Phone: +972 3 6356666
Address:3 Habarzel st.
City: Tel-Aviv
Country: Israel

Recent bed bugs incidents raise concerns of the School districts in seattle king county

“The thing that makes bed bugs so challenging for detection and control is they have excellent abilities to squeeze into cracks and crevices and will often go unnoticed by the casual observer.The majority of bugs will cluster around areas where people will”

Everyone should be wary of acquiring secondhand beds, bedding, and furniture. such items should be examined closely before being brought into the home. Many thrift stores don’t accept mattress donations, and with good reason. When people sleep, skin cells, sweat and bodily fluids seep into their mattress. Add to that the threat of getting bed bugs, building owners should be sufficiently grossed out enough to avoid buying a used bed. This is also true for bedding, including sheets and blankets.

It is doubtful that you grew up with bed bugs and the chances of you having come across 1 over the final fifteen a long time is nonetheless relatively slender, but the possibilities are escalating. In some locations of the world’s internal cities, the incidence of bed bug encounters has improved by up to a hundred%25 for each annum because the year 2000. An additional report states that of seven-hundred hotels surveyed, a quarter of them experienced issues relating to bedbug infestation.

While most mice and rats are harmless, individuals generally do not want them in their properties. You can tell you have these unseemly houseguests by their scent, their seems, and their droppings.

There are other necessary details you require to inquire the pest control company. Know the amount of years they have been in business as well as the number of many years their workers have worked with them, especially the kinds they will deliver to your house. Check if the attending exterminator is an NPCA or National Pest Handle Association member and if he is an accredited inspector of wood destroying bugs. Know if the exterminator who will perform on your house is total time or part time.

Termites are identified to deliver down buildings, cause a great deal of injury to house and even using life by damaging support constructions that people occupy. By now you most likely see how harmful this scenario is when termites are a factor.

Pest extermination is somewhat of an art and there is no person that can defeat Arrow exterminators at that. Over the many years they have developed a trust like nobody has carried out prior to. They have effectively controlled the different pests such as mattress bugs from spreading. Most folks acquire sprays to kill pests and following their use they think that the pests or bugs received’t appear back again. But it is not so. They appear again and leave you red confronted. To properly exterminate them you will have to totally thoroughly clean up the source from exactly where they distribute. You can use the numerous residence solution techniques to handle them along with using the knowledge of the masters like arrow Central district seattle exterminators.

Aside from creating a wide range of diseases, some pests can hurt you by biting, clawing, and stinging. Skilled pest controllers don protective gloves and other things in purchase to maintain pests away from them.

If you must revert to pesticides, choose the kinds that are minimum toxic and have been produced particularly for bed bugs. Professional exterminators must be able to give you seem pieces of advice on the greatest products to use. Also, use pesticides sparingly simply because no make a difference how “safe” they are marketed to be, they will nonetheless include chemicals that could affect your or your family members’s health.

Bed bug extermination is available for homes, offices, multiunit properties and commercial spaces. Professionals can perform inspections, one-time removal or termination and recurring bed bug control services, as well as provide recommendations on preventive measures. Bed bug infestations can affect one bed in one room or an entire home or property. Extermination can take place whether a space is occupied or vacant. Several factors affect the cost of bed bug extermination.

Exterminators often have a set rate they charge per room that includes extermination services for a light to moderate infestation and treatment of a standard amount of furniture. The more rooms that need treatment, the higher the overall cost. Ampm Pest Management in seattle, washington, generally charges $390 per 10×15-foot bedroom for a light to moderate infestation.

The more rampant the bed bug infestation, the higher the cost per room. The higher cost accounts for an increased amount of product needed as well as additional employee time on the job. Ampm Pest control service bed bugs Management charges $380–$480 per bedroom with a standard amount of furniture and a heavy infestation, which is $40–$190 more than services for a light to moderate infestation. The company also provides “peace of mind” services for $200 per room where there is little to no bedbug activity, but the owners want the room treated as well

Media Contact
Company Name: Ampm Bed bug Extermination Service
Contact Person: Daniel Hunts
Phone: 206 571 7580
Address:3213 W Wheeler St
City: Seattle
State: WA
Country: United States

Radical Change Is Coming to an Industry Near You — And It May Kill Off the Companies at the Top of Their Game, According to Innosight

/ — LEXINGTON, MA–(Marketwired – Mar 29, 2017) – The knock-on effects of disruption are hard to predict. Waves of radical innovation have upended the mobile handset business, personal computers, cameras, the publishing industry, the music business and so on. And now, seemingly safe industries — not to mention ones that serve them — are next in the firing line of disruption, according to the growth strategy consulting firm, Innosight.

„The companies most vulnerable to disruption today are those at the top of their game,” says Innosight co-founder and senior partner Mark Johnson, co-author of the forthcoming book Dual Transformation: How to Reposition Today’s Business While Creating the Future (Harvard Business Review Press, April 2017). „In mature industries, incumbent leaders are extremely vulnerable to competitors offering greater simplicity, convenience, accessibility, and affordability.”

„In many cases, these companies think their industries and business models are insulated from disruption because it hasn’t happened yet,” says Scott Anthony, Innosight managing partner and co-author of Dual Transformation. „But earthquakes are preceded by light tremors. Incumbents seldom lose their position overnight. It takes years of incremental change before the shockwaves are large enough to unseat the biggest, safest market leaders. And when that happens, aftershocks can ripple through connected industries, too.”

Who’s Next? The Answer May Surprise You

A look at dozens of industries to assess the potential for market disruption — especially for supposedly safe incumbents — reveals some provocative takeaways:

  • Could driverless cars kill the auto insurance business?
    Cities across the country and around the world are making way for a radical kind of driverless car: one with no steering wheel, no pedals, and nobody inside. Sure, it’s a game changer for car companies. Ford and GM are quickly getting into the „mobility” game, but so is Intel, with its $15 billion purchase of a company that makes sensors and cameras. But what about auto insurers? Companies like Geico and Progressive make most of their money from auto insurance. What happens to their business model when there are no more car accidents?
  • Could consumer banks go the way of VHS players?
    Recent studies have found that millennials hate banks more than just about any other industry. And their options are growing rapidly: telecom companies offering mobile payments; e-commerce companies offering escrow-type payment services; traditional banks losing market share to online banks and non-bank mortgage lenders; even Starbucks held more than $1 billion in prepaid card assets as of 2016. It won’t be long before non-banks and tech companies offer an entire suite of financial services — without the reputational baggage. How soon until consumers „cut the cord” with banks, like they’re doing with cable TV companies?
  • Could 3D printers take a bite out of the shipping business?
    3-D printers can cut labor costs, shorten design and development timelines, improve overall manufacturing efficiency, and even make low-volume manufacturing cost effective. The impact will be felt in a wide variety of manufacturing-dependent industries, like the aerospace, automotive, and medical device industries. But what happens to trucking, logistics, container and rail companies when manufactured goods are smaller, lighter and made closer to where they are used? If you are the business of shipping millions of tons of manufactured goods over long distances, what happens to your business model?
  • Could robots and algorithms replace white-collar professionals?
    They already are. Think: tax preparation software. And the applications for artificial intelligence (AI) are proliferating quickly. The venerated Washington Post is using Heliograph (an AI „bot”) to write breaking news stories for the Post’s website. A Japanese insurance company is replacing human claims workers with a version of IBM’s „Watson” computer. From paralegals to professors, and even radiologists reading x-rays, rapid advancements in AI pose a growing threat to „safe” white-collar jobs.

Responding with a Transformation Agenda

The right way to respond, according to Innosight, is with a „dual transformation” agenda: transform and reposition today’s core business, while building the business of tomorrow in a new, under-served market that can provide rapid growth.

It’s the kind of transformation that Ford Motor Company is undertaking with its focus on „mobility services.” By the time driverless cars take over America’s roads, Ford will be a different company, with a transformed business model, aiming to maintain its leadership position in a radically changed market. Will Ford still make „cars”? Yes. But the identity of the company will be very different: it will no longer be a „car company.”

„There is no such thing as a safe incumbent because disruption is never over,” says Anthony. „But it doesn’t have to mean death for market incumbents. When leaders stop spending too much energy defending the status quo and start preparing for transformation, disruption can create an equal or even greater opportunity and power their next wave of growth. Disruption nearly always creates new markets and opportunities — and incumbents have as much a right to win there as startups do.”

For more information, a copy of Dual Transformation: How to Reposition Today’s Business While Creating the Future or an interview Mark Johnson and Scott Anthony of Innosight, please contact Katarina Wenk-Bodenmiller of Sommerfield Communications at +1 (212) 255-8386 or

Innosight, the strategy and innovation business of global professional services firm Huron, helps organizations design and create the future, instead of being disrupted by it. Acquired by Huron in 2017, Innosight is the leading authority on disruptive innovation and strategic transformation. The company collaborates with clients across a range of industries to identify new growth opportunities, build new ventures and capabilities, and accelerate organizational change. Learn more at and

Navidea Provides Corporate Update and Reports Full Year 2016 Results

DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today reported business and financial highlights for the fourth quarter and year ended December 31, 2016.

2016 Top Highlights

  • Achieved $1 million in Lymphoseek® (technetium Tc 99m tilmanocept) injection commercial milestones upon sale of 100,000th patient dose and receipt of European approval to manufacture a reduced-mass vial
  • Completed sale of Lymphoseek to Cardinal Health 414, LLC (“Cardinal Health 414”) and received approximately $83 million in upfront payments including an advance of $3 million of future earnout payments, with up to $227 million in potential additional earnout payments through 2026
  • Initiated intravenous (“IV”) dose escalation Phase 1 imaging/disease-finding study in rheumatoid arthritis (“RA”) of ten cohorts with three dose cohorts completed with major escalations and imaging of active RA
  • Completed nine-subject cardiovascular imaging disease-finding study in HIV/CV patients and published clinical results in The Journal of Infectious Diseases
  • Awarded $1.8 million Fast-track Small Business Innovation Research (“SBIR”) Grant for Manocept™-based treatment for Kaposi’s Sarcoma (“KS”)
  • Appointed Michael M. Goldberg, M.D., as President and Chief Executive Officer and Eric K. Rowinsky, M.D., as Chairman of the Board of Directors

Business and Product Development Update

This past year and first quarter of 2017 were positively transformative for us. We refocused Navidea from investing in developing the commercial infrastructure to sell its sole commercial imaging product to a late-stage development company focused on several very large imaging market opportunities, and through its Macrophage Therapeutics, Inc. (“MT”) subsidiary successfully advanced a number of novel immunotherapy products through proof of concept studies in animals. In the process, we transformed our capital structure by paying down our high interest and very covenant restrictive debt. The Company has gone from losing close to $28 million in 2015 to a net loss of $14 million in 2016 to operating at cash flow positive projected for 2017 not including discretionary research projects. Furthermore the Company, which had no excess cash flow for discretionary, non grant related research, now has sufficient cash to advance all of our existing imaging and MT ongoing initiatives.

While transforming our business model, balance sheet and income statements, we made significant progress with our technology and pipeline. We are fortunate that both our imaging and therapeutic product candidates are based on the same drug delivery system that targets activated macrophages, even when an additional agent is chemically attached. In humans, we advanced two new delivery approaches and confirmed their utility when dosed subcutaneously or intravenously. In animals, we initiated development of an oral delivery formulation for our therapeutic product candidates.

Additionally, we confirmed that in humans we can target the classically-activated or M1 macrophage in patients with RA and atherosclerosis. This is a major advance, as the alternative activation state, or M2 macrophage, is well known to have significantly higher cell surface expression of the mannose receptor (CD206) than the M1 macrophage in the activated state. Clinical results clearly demonstrate sufficient CD206 expression on M1 activated macrophages to target this receptor with our technology. Our animal studies confirmed as well that targeting either M1 or M2 macrophages implicated in disease is feasible with the appropriate therapeutic linked to our delivery system. In animal models we verified the activity of our product candidates in both M1-based diseases as well as M2-based diseases. Finally, working with various academic groups we demonstrated that by targeting the host macrophage that acts as an incubator we can eliminate viral reservoirs containing Zika, dengue, human immunodeficiency virus (“HIV”), human herpesvirus 8 (“HHV8”), and other infectious agents such as leishmaniosis. We are also currently working with National Institutes of Health (“NIH”)-funded labs, at no cost to Navidea, to explore our antiviral and anti-infective performance in appropriate animal models.

Financial Results

Revenues for the year ended December 31, 2016 were $22.0 million compared to $13.2 million for 2015. Navidea’s revenues for 2016 consisted of $17.0 million in sales of Lymphoseek, $3.1 million from various federal grants and other revenue, and $1.8 million related to license agreements, compared to $10.3 million, $1.9 million and $1.1 million, respectively, for 2015.

Operating expenses for the year ended December 31, 2016 were approximately $21.9 million compared to $30.0 million for 2015. Research and development expenses were $8.9 million during 2016 compared to $12.8 million during 2015. The net decrease was primarily a result of reductions in NAV4694, Lymphoseek and NAV5001 product development costs coupled with reduced headcount and related support costs, offset by increased Manocept diagnostic and therapeutic product development costs. Selling, general and administrative expenses were approximately $13.0 million for 2016 compared to $17.3 million for 2015. The net decrease was primarily due to reduced headcount and related support costs, contracted medical science liaisons, business development consulting services, market development expenses related to Lymphoseek, and investor relations, offset by increased legal and professional services.

Navidea’s loss from operations for the year ended December 31, 2016 was $2.2 million compared to $18.6 million for 2015. For the year ended December 31, 2016, Navidea reported a loss attributable to common stockholders of $14.3 million, or $0.09 per share, compared to a loss attributable to common stockholders of $27.6 million, or $0.18 per share, for the same period in 2015.

Revenues for the fourth quarter of 2016 were $3.4 million compared to $4.3 million for the same period in 2015. Navidea’s revenues for the fourth quarter of 2016 consisted of $2.3 million in sales of Lymphoseek and $1.0 million from various federal grants and other revenue, compared to $3.5 million and $541,000, respectively, coupled with $250,000 related to license agreements, for the same period in 2015. Additionally, approximately $2 million in sales of Lymphoseek to Cardinal Health 414 recorded in the third quarter of 2016 was accelerated to help facilitate the transaction that was ultimately closed in March 2017. Without acceleration of such, the related sales would have occurred in the fourth quarter of 2016.

Fourth quarter 2016 operating expenses were $5.5 million compared to $6.4 million for the fourth quarter of 2015. Research and development expenses were $2.4 million during the fourth quarter of 2016 compared to $2.6 million during the fourth quarter of 2015. The net decrease from 2015 to 2016 was primarily a result of reduced headcount and related support costs coupled with decreased NAV4694 product development costs, offset by increased Manocept diagnostic and Lymphoseek product development costs. Selling, general and administrative expenses were $3.1 million for the fourth quarter of 2016 compared to $3.8 million for the same period in 2015. The net decrease was primarily due to reduced headcount and related support costs, market development expenses related to Lymphoseek and investor relations, offset by increased legal and professional services.

Navidea’s loss from operations for the fourth quarter of 2016 was $2.4 million compared to $2.6 million for the fourth quarter of 2015. For the fourth quarter of 2016, Navidea reported a loss attributable to common stockholders of $3.9 million, or $0.02 per share, compared to a loss attributable to common stockholders of $2.5 million, or $0.02 per share, for the fourth quarter of 2015.

Detailed Highlights

  • Navidea and Cardinal Health 414
    • Completed sale of Lymphoseek to Cardinal Health 414 for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic spread to lymph nodes for the staging of cancer in North America
    • Received approximately $83 million in upfront payments including an advance of $3 million of future earnout payments, with up to $227 million in potential additional earnout payments through 2026, $17.1 million of which is guaranteed over the next three years
  • CRG et al
    • Entered into a Global Settlement Agreement between the Company, MT, Capital Royalty Partners II L.P. and its affiliates (“CRG”), and Cardinal Health 414 in which Navidea repaid $59 million (the “Deposit Amount”) of its indebtedness and other obligations outstanding under the CRG Term Loan.
  • Platinum et al
    • Concurrently with payment of the Deposit Amount to CRG, the Company also paid to Platinum Partners Credit Opportunities Master Fund, LP (“PPCO”) an aggregate of $7.7 million in partial satisfaction of the Company’s liabilities, obligations and indebtedness under that certain Loan Agreement, dated July 25, 2012 (as amended) by and between the Company and Platinum-Montaur Life Sciences, LLC, which, to the extent of such payment, were transferred by Platinum-Montaur to PPCO. Approximately $1.9 million remains outstanding under the Platinum Loan Agreement.
  • U.S. Food and Drug Administration (“FDA”)
    • Held several discussions/meetings with the FDA significantly expediting development and approval timelines for Manocept-RA disease-finding approaches to rheumatoid arthritis
  • Cardiovascular (“CV”) Initiative
    • Completed nine-subject cardiovascular imaging disease-finding study in HIV/CV patients
    • Presented clinical results at CROI-2017 and published in the Journal of Infectious Disease
    • Additional planned studies include a large potential partner evaluating product in their proprietary animal models
  • Rheumatoid Arthritis
    • Completed 18-subject subcutaneous (“SC”) Manocept RA study
    • Initiated RA intravenous (“IV”) dose escalation Phase 1 imaging/disease-finding study of 10 cohorts with three dose cohorts completed with major escalations and imaging of active RA
    • Appointed strategic clinical and regulatory consulting firm to optimize clinical development plan for RA imaging candidate
  • Non-Alcoholic Steatohepatitis (NASH) Therapy
    • Completed three in vivo studies employing two Manocept conjugate agents and three different dosing regimens demonstrating effectiveness at preventing non-alcoholic fatty liver disease (“NAFLD”) progression to NASH and NASH’s progression to liver cirrhosis
    • A poster presentation on certain of our NASH results will be presented at a meeting next week and will be posted on the MT website
  • Cancer Therapy
    • Completed three preclinical studies, two single agent and one in combination with a well-established therapeutic antibody (two confirmatory in vivo studies – murine human tumor model). All three studies confirmed a positive impact on the tumor progression and inhibition/tumor kill.
  • Cancer Imaging to Treatment
    • Colorectal Cancer and Liver Cancer – completed preclinical testing for the requirements to administer the Manocept imaging agent for colorectal cancer and colorectal cancer with synchronous liver metastases.
    • Cervical Cancer – completed a significant portion of the clinical testing for a new indication for imaging of metastatic disease (lymph node metastasis) in cervical cancer. Navidea’s portion of the study will be completed in Q1 2017.
  • Lipid Storage Disease (Neuro)
    • Initiated in vitro cell culture study in which Manocept conjugates demonstrated substantial protective effect of glial cells exposed to toxic metabolite
  • Anti-Infectives
    • Zika Virus – Initiated and completed four in vitro studies in human tissue demonstrating a highly effective reduction in Zika infectivity and antiviral activity by multiple Manocept conjugates
    • Dengue Virus – Initiated and completed four in vitro studies in human tissue demonstrating a highly effective reduction in dengue infectivity and antiviral activity by multiple Manocept conjugates
    • Leishmaniosis – Initiated and completed two in vivo studies demonstrating a highly effective targeting in Leishmaniosis infectivity and parasite activity by multiple Manocept conjugates
    • Cytomegalovirus (“CMV”) – Held discussions with NIH/NIAID on testing of key Manocept conjugates in CMV infection and disease progression with preclinical studies to be initiated in H2 2017
  • Kaposi’s Sarcoma
    • Received NIH/NCI funding to support the therapeutic development of anticancer (Anti-KS) Manocept conjugates
    • Phase 1 of the grant completed and Phase 2 clinical protocols are IRB-approved with study initiation anticipated shortly
    • Human Herpes Virus 8 – The testing of Manocept agents against HHV8 are an integral part of the Kaposi’s Sarcoma therapy initiatives
    • Human Immunodeficiency Virus – The testing of Manocept agents against HIV is an integral part of the KS therapy initiatives
  • Completed Preclinical FDA requirements for IV administration of tilmanocept for all radio-diagnostic applications
  • Inflammatory Bowel Disease and Crohn’s Disease (“BD/C”)
    • Initiated partnership with major pharma group to assess the efficacy of Manocept conjugates in appropriate in vivo models with results anticipated in the coming months.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. The development activities of the Manocept immunotherapeutic platform will be conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit

December 31, December 31,
2016 2015


Cash $ 1,539,325 $ 7,166,260
Restricted cash 5,001,253
Other current assets 4,285,691 5,410,914
Non-current assets   1,635,407     2,387,339  
Total assets $ 12,461,676   $ 14,964,513  
Liabilities and stockholders’ deficit:
Deferred revenue, current $ 2,315,037 $ 1,044,281
Notes payable, current 51,957,913 333,333
Other current liabilities 15,588,838 4,806,236
Notes payable, net of discount 9,641,179 60,746,002
Other liabilities   624,922     1,870,361  
Total liabilities   80,127,889     68,800,213  
Navidea stockholders’ deficit (68,135,123 ) (54,305,258 )
Noncontrolling interest   468,910     469,558  
Total stockholders’ deficit   (67,666,213 )   (53,835,700 )
Total liabilities and stockholders’ deficit $ 12,461,676   $ 14,964,513  
Three Months Ended Twelve Months Ended
December 31, December 31, December 31, December 31,
2016 2015 2016 2015
(unaudited) (unaudited) (unaudited)  
Lymphoseek sales revenue $ 2,332,609 $ 3,502,860 $ 17,037,098 $ 10,254,352
Lymphoseek license revenue 250,000 1,795,625 1,133,333
Grant and other revenue   1,022,988     540,806     3,136,983     1,861,622  
Total revenue   3,355,597     4,293,666     21,969,706     13,249,307  
Cost of good sold   279,554     515,386     2,297,040     1,754,763  
Gross profit   3,076,043     3,778,280     19,672,666     11,494,544  
Operating expenses:
Research and development 2,421,422 2,607,216 8,882,576 12,787,733
Selling, general and administrative   3,087,991     3,771,753     13,013,565     17,257,329  
Total operating expenses   5,509,413     6,378,969     21,896,141     30,045,062  
Loss from operations   (2,433,370 )   (2,600,689 )   (2,223,475 )   (18,550,518 )
Other income (expense):
Interest expense, net (2,573,101 ) (2,183,050 ) (14,861,270 ) (6,873,736 )
Equity in the loss of joint venture (10,036 ) (15,159 ) (305,253 )
Loss on disposal of joint venture (39,732 )
Change in fair value of financial instruments 1,102,535 1,088,120 2,858,524 (614,782 )
Loss on extinguishment of debt (2,440,714 )
Other income (expense), net   21,997     708     (27,919 )   26,808  
Net loss (3,881,939 ) (3,704,947 ) (14,309,031 ) (28,758,195 )
Benefit from income taxes       436,051         436,051  
Loss from continuing operations (3,881,939 ) (3,268,896 ) (14,309,031 ) (28,322,144 )
Income from discontinued operations, net of tax       758,609         758,609  
Net loss (3,881,939 ) (2,510,287 ) (14,309,031 ) (27,563,535 )
Less loss attributable to noncontrolling interest (132 ) (174 ) (648 ) (855 )
Deemed dividend on beneficial conversion feature               (46,000 )
Net loss attributable to common stockholders $ (3,881,807 ) $ (2,510,113 ) $ (14,308,383 ) $ (27,608,680 )
Loss per common share (basic and diluted):
Continuing operations $ (0.02 ) $ (0.02 ) $ (0.09 ) $ (0.19 )
Discontinued operations $ $ 0.00 $ $ 0.01
Attributable to common stockholders $ (0.02 ) $ (0.02 ) $ (0.09 ) $ (0.18 )
Weighted average shares outstanding
(basic and diluted) 155,516,120 154,591,487 155,422,384 151,180,222

Democratic Republic of the Congo Travel Warning

The Department of State warns U.S. citizens to avoid unnecessary travel to the DRC. Very poor transportation infrastructure throughout the country and poor security conditions in eastern DRC make it difficult for the U.S. Embassy to provide consular services anywhere outside of Kinshasa.  All U.S. citizens should have evacuation plans that do not rely solely on U.S. government assistance.  This replaces the Travel Warning dated December 23, 2016.

Armed groups, bandits, and some elements of the Congolese armed forces operate in the provinces of North and South Kivu, Bas-Uele, Haut-Uele, Ituri, Tanganyika, Haut-Lomami, and the Kasai region. These groups have been known to kill, rape, kidnap, pillage, and carry out military or paramilitary operations in which civilians may be indiscriminately targeted. 

Congolese military and United Nations forces continue to operate throughout North and South Kivu and near the DRC’s borders with the Central African Republic and the Republic of South Sudan, particularly in and around Garamba National Park. Travelers in the region may encounter troop movements, armored vehicles and attack helicopters. Kidnapping for ransom is also common, particularly in areas north and west of Goma, North Kivu. 

For further information: